Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosisRuben A. Mesa, Srđan Verstovšek, Donal P. McLornan et al.|Leukemia|2022Cited by 63